UY38990A - Derivados de pirazolilo útiles como agentes anticancerígenos - Google Patents
Derivados de pirazolilo útiles como agentes anticancerígenosInfo
- Publication number
- UY38990A UY38990A UY0001038990A UY38990A UY38990A UY 38990 A UY38990 A UY 38990A UY 0001038990 A UY0001038990 A UY 0001038990A UY 38990 A UY38990 A UY 38990A UY 38990 A UY38990 A UY 38990A
- Authority
- UY
- Uruguay
- Prior art keywords
- cancer agents
- derivatives useful
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de fórmula (I) o un estereoisómero del mismo, o un atropisómero del mismo, o una sal farmacéuticamente aceptable del mismo, o una sal farmacéuticamente aceptable de un estereoisómero del mismo, o una sal farmacéuticamente aceptable de un atropisómero del mismo;(I) un método para fabricar dicho compuesto y sus usos terapéuticos. La presente invención proporciona además una combinación de agentes farmacológicamente activos y una composición farmacéutica que comprende dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951400P | 2019-12-20 | 2019-12-20 | |
| PCT/CN2020/125425 WO2021120890A1 (en) | 2019-12-20 | 2020-10-30 | Pyrazolyl derivatives useful as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38990A true UY38990A (es) | 2021-07-30 |
Family
ID=76477081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038990A UY38990A (es) | 2019-12-20 | 2020-12-17 | Derivados de pirazolilo útiles como agentes anticancerígenos |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11702409B2 (es) |
| EP (2) | EP4076662B1 (es) |
| JP (2) | JP2023506841A (es) |
| KR (1) | KR20220114064A (es) |
| CN (1) | CN114929342A (es) |
| AR (1) | AR120855A1 (es) |
| AU (1) | AU2020410531B2 (es) |
| CA (1) | CA3165148A1 (es) |
| CL (1) | CL2022001625A1 (es) |
| CO (1) | CO2022008344A2 (es) |
| CR (1) | CR20220281A (es) |
| DK (1) | DK4076662T3 (es) |
| DO (1) | DOP2022000124A (es) |
| EC (1) | ECSP22047876A (es) |
| FI (1) | FI4076662T3 (es) |
| IL (1) | IL293893A (es) |
| JO (1) | JOP20220155A1 (es) |
| LT (1) | LT4076662T (es) |
| MX (1) | MX2022007350A (es) |
| PE (1) | PE20221910A1 (es) |
| PT (1) | PT4076662T (es) |
| TW (1) | TW202136241A (es) |
| UY (1) | UY38990A (es) |
| WO (2) | WO2021120890A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| US11945812B2 (en) | 2020-06-02 | 2024-04-02 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| TW202233607A (zh) * | 2020-10-30 | 2022-09-01 | 瑞士商諾華公司 | Ｋｒａｓ ｇ１２ｃ抑制劑化合物之新結晶形式 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| BR112023012301A2 (pt) * | 2020-12-22 | 2023-10-03 | Novartis Ag | Combinações farmacêuticas que compreendem um inibidor de kras g12c e usos de um inibidor de kras g12c para o tratamento de cânceres |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
| WO2022246459A1 (en) * | 2021-05-19 | 2022-11-24 | Genentech, Inc. | Combination therapy |
| CA3218712A1 (en) * | 2021-06-23 | 2022-12-29 | Novartis Ag | Pyrazolyl derivatives as inhibitors of the kras mutant protein |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| JPWO2023008462A1 (es) | 2021-07-27 | 2023-02-02 | ||
| TW202327569A (zh) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| US20230202984A1 (en) | 2021-11-24 | 2023-06-29 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023097194A2 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023099592A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| WO2023122662A1 (en) | 2021-12-22 | 2023-06-29 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| WO2023143605A1 (en) * | 2022-01-31 | 2023-08-03 | Novartis Ag | Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| CN116478141B (zh) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | 氘代kras抑制剂药物及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1199600A (en) * | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| EP1786803A1 (en) | 2004-08-31 | 2007-05-23 | Biogen Idec MA, Inc. | Pyrimidinylpyrazoles as tgf-beta inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US8703805B2 (en) * | 2005-06-27 | 2014-04-22 | Exelixis Patent Company Llc | Modulators of LXR |
| CA2643066A1 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| EP2170337A4 (en) | 2007-06-28 | 2013-12-18 | Abbvie Inc | NEW TRIAZOLOPYRIDAZINE |
| EP2173728A2 (en) * | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| CA2695114A1 (en) * | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| CA2731146C (en) | 2008-07-24 | 2016-05-03 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| WO2010108268A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2601185B1 (en) * | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| AU2014239542A1 (en) | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| AU2014331794C1 (en) | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| CA2981530A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN108069955B (zh) | 2016-11-14 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用 |
| BR112019008516A2 (pt) | 2016-11-14 | 2019-07-09 | Jiangsu Hengrui Medicine Co | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo |
| UA124474C2 (uk) | 2016-12-22 | 2021-09-22 | Емджен Інк. | БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| MX2020005063A (es) | 2017-11-15 | 2021-01-08 | Mirati Therapeutics Inc | Inhibidores de kras g12c. |
| WO2019136147A1 (en) * | 2018-01-03 | 2019-07-11 | The Board Of Trustees Of The University Of Illinois | Toll-like receptor signaling inhibitors |
| MX2020008852A (es) * | 2018-02-23 | 2020-10-14 | Samumed Llc | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas. |
| US11090304B2 (en) * | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CA3099045A1 (en) * | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| JP7360396B2 (ja) * | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法 |
-
2020
- 2020-10-30 WO PCT/CN2020/125425 patent/WO2021120890A1/en not_active Application Discontinuation
- 2020-12-17 WO PCT/IB2020/062144 patent/WO2021124222A1/en active Application Filing
- 2020-12-17 JP JP2022536692A patent/JP2023506841A/ja active Pending
- 2020-12-17 JO JOP/2022/0155A patent/JOP20220155A1/ar unknown
- 2020-12-17 PT PT208293654T patent/PT4076662T/pt unknown
- 2020-12-17 LT LTEPPCT/IB2020/062144T patent/LT4076662T/lt unknown
- 2020-12-17 KR KR1020227024285A patent/KR20220114064A/ko unknown
- 2020-12-17 FI FIEP20829365.4T patent/FI4076662T3/fi active
- 2020-12-17 AU AU2020410531A patent/AU2020410531B2/en active Active
- 2020-12-17 CA CA3165148A patent/CA3165148A1/en active Pending
- 2020-12-17 DK DK20829365.4T patent/DK4076662T3/da active
- 2020-12-17 UY UY0001038990A patent/UY38990A/es unknown
- 2020-12-17 MX MX2022007350A patent/MX2022007350A/es unknown
- 2020-12-17 CR CR20220281A patent/CR20220281A/es unknown
- 2020-12-17 US US17/125,335 patent/US11702409B2/en active Active
- 2020-12-17 PE PE2022001123A patent/PE20221910A1/es unknown
- 2020-12-17 IL IL293893A patent/IL293893A/en unknown
- 2020-12-17 CN CN202080089867.2A patent/CN114929342A/zh active Pending
- 2020-12-17 EP EP20829365.4A patent/EP4076662B1/en active Active
- 2020-12-17 EP EP24151713.5A patent/EP4344702A3/en active Pending
- 2020-12-18 TW TW109145169A patent/TW202136241A/zh unknown
- 2020-12-21 AR ARP200103593A patent/AR120855A1/es unknown
-
2022
- 2022-06-15 CO CONC2022/0008344A patent/CO2022008344A2/es unknown
- 2022-06-15 CL CL2022001625A patent/CL2022001625A1/es unknown
- 2022-06-15 EC ECSENADI202247876A patent/ECSP22047876A/es unknown
- 2022-06-15 DO DO2022000124A patent/DOP2022000124A/es unknown
-
2024
- 2024-01-22 JP JP2024007468A patent/JP2024056707A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022008344A2 (es) | 2022-06-30 |
| ECSP22047876A (es) | 2022-07-29 |
| US11702409B2 (en) | 2023-07-18 |
| AR120855A1 (es) | 2022-03-23 |
| IL293893A (en) | 2022-08-01 |
| EP4344702A2 (en) | 2024-04-03 |
| CA3165148A1 (en) | 2021-06-24 |
| EP4344702A3 (en) | 2024-04-10 |
| EP4076662B1 (en) | 2024-01-31 |
| CN114929342A (zh) | 2022-08-19 |
| JP2023506841A (ja) | 2023-02-20 |
| MX2022007350A (es) | 2022-07-19 |
| WO2021124222A1 (en) | 2021-06-24 |
| LT4076662T (lt) | 2024-05-10 |
| CR20220281A (es) | 2022-07-01 |
| WO2021120890A1 (en) | 2021-06-24 |
| DOP2022000124A (es) | 2022-07-31 |
| EP4076662A1 (en) | 2022-10-26 |
| US20220363670A1 (en) | 2022-11-17 |
| JOP20220155A1 (ar) | 2023-01-30 |
| PE20221910A1 (es) | 2022-12-23 |
| TW202136241A (zh) | 2021-10-01 |
| KR20220114064A (ko) | 2022-08-17 |
| DK4076662T3 (da) | 2024-04-22 |
| FI4076662T3 (fi) | 2024-04-24 |
| JP2024056707A (ja) | 2024-04-23 |
| PT4076662T (pt) | 2024-04-18 |
| AU2020410531A1 (en) | 2022-07-28 |
| CL2022001625A1 (es) | 2023-03-24 |
| AU2020410531B2 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CO6781541A2 (es) | Derivados glucósidos y usos de los mismos | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| UY36124A (es) | Derivados de carboxamida | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| UY36123A (es) | Derivados de carboxamida | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2021012559A2 (es) | Compuestos macrocíclicos como agonistas de sting | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| CL2022002490A1 (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| CO2022004768A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CU20160170A7 (es) | Derivados de carboxamida |